Brexucabtagene Autoleucel

Preferred Label : Brexucabtagene Autoleucel;

NCIt synonyms : Anti-CD19 Autologous CAR-CD28 T-cells KTE-X19; Brexu-cel;

NCIt definition : A preparation of autologous peripheral blood T-lymphocytes (PBTL) that have been transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 single chain variable fragment (scFv) coupled to the costimulatory signaling domain CD28 and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3 zeta), with potential immunostimulating and antineoplastic activities. Upon intravenous infusion and re-introduction of abrexucabtagene autoleucel into the patient, these cells bind to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen that is expressed in all B-cell lineage malignancies. CD3 zeta is one of several membrane-bound polypeptides found in the TCR/CD3 complex; it regulates both the assembly and cell surface expression of TCR complexes. CD28 is essential for CD4 T-cell proliferation, interleukin-2 production, and T-helper type-2 (Th2) development. KTE-X19 has the same construct as axicabtagene ciloleucel, but differs in the manufacturing process in that KTE-X19 includes specific T-cell selection and lymphocyte enrichment necessary for activity against certain B-cell malignancies.;

UNII : 4MD2J2T8SJ;

Drug name : Tecartus;

Molecule name : KTE-X19; KTE X19;

NCI Metathesaurus CUI : CL1382898;

Codes from synonyms : 6632;

Details

Origin ID

C170439;

UMLS CUI

C5398046;

Currated CISMeF NLP mapping
- Brexucabtagene autoleucel [SMS substance]
- Brexucabtagene autoleucel (substance) [SNOMED CT concept]
- brexucabtagene autoleucel [MeSH concept]
- brexucabtagene autoleucel [MeSH Supplementary Concept]
See also inter- (CISMeF)
- Product containing brexucabtagene autoleucel (medicinal product) [SNOMED CT concept]
Semantic type(s)
- Cell [UMLS semantic type]
UMLS correspondences (same concept)
- Brexucabtagene autoleucel (substance) [SNOMED CT concept]
- Product containing brexucabtagene autoleucel (medicinal product) [SNOMED CT concept]
- brexucabtagene autoleucel [MeSH Supplementary Concept]
- brexucabtagene autoleucel [ATC Code]
Validated automatic mappings to BTNT
- brexucabtagene autoleucel [ATC Code]
chemical_or_drug_affects_cell_type_or_tissue
- Cytotoxic T-Lymphocyte [NCIt concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Sensitization [NCIt concept]
chemical_or_drug_has_physiologic_effect
- Immunopotentiation [NCIt concept]
- T-Cell Activation [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- HemOnc Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- B-Lymphocyte Antigen CD19 [NCIt concept]
is_component_of_chemotherapy_regimen
- Brexucabtagene Autoleucel Regimen [NCIt concept]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients